再鼎医药-话题@MedSci

#再鼎医药#

13篇内容 | 895人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2146953, encodeId=73bd2146953c8, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a><a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>新药皮下注射剂型<a href='/topic/show?id=a38910639454' target=_blank style='color:#2F92EE;'>#艾加莫德α#</a>注射液国内申报上市, objectTitle=再鼎医药重症肌无力新药皮下注射剂型艾加莫德α注射液国内申报上市, objectType=article, longId=780687, objectId=4e08e80687a1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230707/148c7be94c9c4d2babd5745efd0ac569.jpg, objectUrl=/article/show_article.do?id=4e08e80687a1, replyNumber=0, likeNumber=43, createdTime=2023-07-08, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4e08e80687a1, moduleTitle=再鼎医药重症肌无力新药皮下注射剂型艾加莫德α注射液国内申报上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e08e80687a1)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1389629, encodeId=a61b13896297f, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=FDA批准Ripretinib用于四线晚期胃肠道间质瘤治疗！再鼎医药持有中国权益, objectType=article, longId=194393, objectId=2d8619439350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d8619439350, replyNumber=0, likeNumber=33, createdTime=2020-05-20, rootId=0, userName=ms7514935887898259, userId=78d82500042, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d8619439350, moduleTitle=FDA批准Ripretinib用于四线晚期胃肠道间质瘤治疗！再鼎医药持有中国权益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d8619439350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389628, encodeId=76021389628f9, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=NMPA：批准再鼎医药肿瘤电场疗法用于胶质母细胞瘤治疗上市，开创治疗新纪元, objectType=article, longId=194137, objectId=d84319413e55, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d84319413e55, replyNumber=0, likeNumber=41, createdTime=2020-05-15, rootId=0, userName=ms7514935887898259, userId=78d82500042, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d84319413e55, moduleTitle=NMPA：批准再鼎医药肿瘤电场疗法用于胶质母细胞瘤治疗上市，开创治疗新纪元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d84319413e55)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389627, encodeId=f071138962e69, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=再鼎医药新型抗生素——奥玛环素上市申请获NMPA优先审评, objectType=article, longId=193902, objectId=a4ea193902d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4ea193902d3, replyNumber=0, likeNumber=45, createdTime=2020-05-12, rootId=0, userName=ms7514935887898259, userId=78d82500042, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4ea193902d3, moduleTitle=再鼎医药新型抗生素——奥玛环素上市申请获NMPA优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4ea193902d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389626, encodeId=e1a313896266e, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=再鼎医药的PARP抑制剂Niraparib用于卵巢癌维持治疗，获得NMPA授予优先审查, objectType=article, longId=192482, objectId=1c3c1924827f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c3c1924827f, replyNumber=0, likeNumber=41, createdTime=2020-04-20, rootId=0, userName=ms7514935887898259, userId=78d82500042, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c3c1924827f, moduleTitle=再鼎医药的PARP抑制剂Niraparib用于卵巢癌维持治疗，获得NMPA授予优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c3c1924827f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389625, encodeId=a81e1389625e5, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=再生元与再鼎医药合作开发REGN1979（CD20xCD3双特异性抗体），治疗非霍奇金淋巴瘤, objectType=article, longId=191863, objectId=981f191863d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=981f191863d9, replyNumber=0, likeNumber=36, createdTime=2020-04-11, rootId=0, userName=ms7514935887898259, userId=78d82500042, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=981f191863d9, moduleTitle=再生元与再鼎医药合作开发REGN1979（CD20xCD3双特异性抗体），治疗非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=981f191863d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389624, encodeId=26c213896249e, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=瀚晖制药与再鼎医药达成战略合作，携手并肩探索全球领先抗感染药物, objectType=article, longId=190509, objectId=666a1905093b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=666a1905093b, replyNumber=0, likeNumber=44, createdTime=2020-03-22, rootId=0, userName=ms7514935887898259, userId=78d82500042, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=666a1905093b, moduleTitle=瀚晖制药与再鼎医药达成战略合作，携手并肩探索全球领先抗感染药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=666a1905093b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389623, encodeId=ffb6138962390, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=喜讯！陈列平教授加入再鼎医药科学顾问委员会, objectType=article, longId=159385, objectId=217a159385a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=217a159385a5, replyNumber=0, likeNumber=40, createdTime=2019-02-03, rootId=0, userName=ms7514935887898259, userId=78d82500042, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=217a159385a5, moduleTitle=喜讯！陈列平教授加入再鼎医药科学顾问委员会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=217a159385a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389622, encodeId=a78f1389622e0, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=再鼎医药香港上市肿瘤电场治疗产品Optune, objectType=article, longId=157074, objectId=5c1f15e074f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c1f15e074f8, replyNumber=0, likeNumber=35, createdTime=2019-01-01, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c1f15e074f8, moduleTitle=再鼎医药香港上市肿瘤电场治疗产品Optune, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c1f15e074f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389621, encodeId=8979138962121, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=再鼎医药获得美国生物公司MacroGenics三款在研产品的中国区域开发及商业化**授权, objectType=article, longId=154875, objectId=03751548e558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03751548e558, replyNumber=0, likeNumber=0, createdTime=2018-12-02, rootId=0, userName=ms7514935887898259, userId=78d82500042, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03751548e558, moduleTitle=再鼎医药获得美国生物公司MacroGenics三款在研产品的中国区域开发及商业化**授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03751548e558)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389620, encodeId=c5b31389620ff, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=前阿斯利康副总裁梁怡去向再鼎医药，外资高管纷纷回流国内创新药企, objectType=article, longId=140102, objectId=9b121401021e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b121401021e, replyNumber=0, likeNumber=36, createdTime=2018-06-07, rootId=0, userName=ms7514935887898259, userId=78d82500042, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b121401021e, moduleTitle=前阿斯利康副总裁梁怡去向再鼎医药，外资高管纷纷回流国内创新药企, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b121401021e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389619, encodeId=bfe013896194d, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=再鼎医药宣布在美首次公开发行ADS股票发行价, objectType=article, longId=113783, objectId=edc1113e8335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edc1113e8335, replyNumber=0, likeNumber=37, createdTime=2017-09-24, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edc1113e8335, moduleTitle=再鼎医药宣布在美首次公开发行ADS股票发行价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edc1113e8335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1389618, encodeId=300e1389618ae, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, objectTitle=中国新锐公司再鼎医药正式申请赴美上市, objectType=article, longId=109162, objectId=956410916276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=956410916276, replyNumber=0, likeNumber=44, createdTime=2017-08-20, rootId=0, userName=ms7514935887898259, userId=78d82500042, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=956410916276, moduleTitle=中国新锐公司再鼎医药正式申请赴美上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=956410916276)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

再鼎医药

2020-05-29

(审核中...)

前往app查看评论内容

#再鼎医药##重症肌无力#新药皮下注射剂型#艾加莫德α#注射液国内申报上市

再鼎医药重症肌无力新药皮下注射剂型艾加莫德α注射液国内申报上市

2023-07-08发表于上海

ms7514935887898259 (审核中...)

前往app查看评论内容

#再鼎医药#

FDA批准Ripretinib用于四线晚期胃肠道间质瘤治疗！再鼎医药持有中国权益

2020-05-20

ms7514935887898259 (审核中...)

前往app查看评论内容

#再鼎医药#

NMPA：批准再鼎医药肿瘤电场疗法用于胶质母细胞瘤治疗上市，开创治疗新纪元

2020-05-15

ms7514935887898259 (审核中...)

前往app查看评论内容

#再鼎医药#

再鼎医药新型抗生素——奥玛环素上市申请获NMPA优先审评

2020-05-12

ms7514935887898259 (审核中...)

前往app查看评论内容

#再鼎医药#

再鼎医药的PARP抑制剂Niraparib用于卵巢癌维持治疗，获得NMPA授予优先审查

2020-04-20

ms7514935887898259 (审核中...)

前往app查看评论内容

#再鼎医药#

再生元与再鼎医药合作开发REGN1979（CD20xCD3双特异性抗体），治疗非霍奇金淋巴瘤

2020-04-11

ms7514935887898259 (审核中...)

前往app查看评论内容

#再鼎医药#

瀚晖制药与再鼎医药达成战略合作，携手并肩探索全球领先抗感染药物

2020-03-22

ms7514935887898259 (审核中...)

前往app查看评论内容

#再鼎医药#

喜讯！陈列平教授加入再鼎医药科学顾问委员会

2019-02-03

爆笑小医 (审核中...)

前往app查看评论内容

#再鼎医药#

再鼎医药香港上市肿瘤电场治疗产品Optune

2019-01-01

ms7514935887898259 (审核中...)

前往app查看评论内容

#再鼎医药#

再鼎医药获得美国生物公司MacroGenics三款在研产品的中国区域开发及商业化**授权

2018-12-02

ms7514935887898259 (审核中...)

前往app查看评论内容

#再鼎医药#

前阿斯利康副总裁梁怡去向再鼎医药，外资高管纷纷回流国内创新药企

2018-06-07

docwu2019 (审核中...)

前往app查看评论内容

#再鼎医药#

再鼎医药宣布在美首次公开发行ADS股票发行价

2017-09-24

ms7514935887898259 (审核中...)

前往app查看评论内容

#再鼎医药#

中国新锐公司再鼎医药正式申请赴美上市

2017-08-20

科室
- - 订阅+
  - 更多科室
工具
服务